The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Hospira, Inc., a Pfizer company, is recalling the above referenced lot of **Dopamine HCl Injection, USP.** Pfizer initiated this recall due to a GMP deviation during manufacturing where there was potential product exposure to extrinsic particles and impurities.
Pfizer has completed a Health Hazard Assessment which concluded that the overall potential risk to the patient arising from this issue is considered to be low. The use of impacted product has a potential of being associated with adverse events which could be serious to critical in severity, such as reduced therapeutic effectiveness, toxicity, allergic reactions, vascular occlusion, pulmonary embolism, inflammation, phlebitis, thrombophlebitis, or microvascular tissue injury.

To date, Pfizer has not received reports of any adverse events associated with this issue.

PRODUCT: Dopamine HCl Injection, USP 200 mg/5 ml (40 mg/ml)

NDC NUMBER: Carton NDC Number: 0409-5820-01
Vial NDC Number: 0409-5820-11

LOT NUMBER: NL5230

EXPIRATION DATE: OCTOBER 2027